TABLE 2.
ATI-2173 cross-resistancea
| Mutation | EC50 in μM |
||||
|---|---|---|---|---|---|
| ATI-2173 | Entecavir | Lamivudine | GLS4 | AT-130 | |
| Wild type | 0.601 | 0.003 | 0.096 | 0.015 | 0.246 |
| rtM204I | >10 | — | >10 | — | — |
| rtV173L+M204I | >10 | — | >10 | — | — |
| rtM204V | 0.162 | — | 3.509 | — | — |
| rtL180M+M204V | >10 | — | >10 | — | — |
| rtS202G+M204I+M250V | >10 | 20.995 | — | — | — |
| rtS202G+M204I | >10 | 9.962 | — | — | — |
| rtA181V | >10 | — | 0.210 | — | — |
| rtN236T | 0.386 | — | 0.130 | — | — |
| coreP25A | 0.537 | — | — | 0.295 | — |
| coreT33N | 0.338 | — | — | 3.081 | >10 |
a
ATI-2173 was tested against eight nucleoside-resistant HBV genotypes and two cpAM-resistant HBV genotypes. Symbol —, not applicable.